Novo Sees Generic Ozempic Delayed in China Until Next Year

Novo Nordisk A/S expects generic Ozempic to be delayed in China until next year, a positive step for the drugmaker as it battles to keep its share of the global obesity market.

The patent for semaglutide, the main ingredient in the blockbusters Ozempic and Wegovy, expired in China in March, sparking expectations for generic competition and falling prices. But Ozempic is entitled to regulatory data protection until April 2027 under the China-Switzerland Free Trade Agreement, the drugmaker said Wednesday.